ACORYS
Commercial- Indications
- Cardiac arrhythmia, Atrial fibrillation
Company intelligence / Profile preview
Corify Care has developed ACORYS, a non-invasive real-time global cardiac mapping device that enables clinicians to visualize the heart’s electrical activity using body-surface sensors. Clinical studies show an ablation success rate of nearly double traditional methods for atrial fibrillation patients. The company achieved CE marking under MDR in July 2024 after pivotal trials involving over a thousand patients. Expansion into Germany and the US—with FDA approval anticipated—is underway. Next-generation systems will integrate AI and digital twins to further personalize arrhythmia care.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Corify Care.